7 citations,
June 2020 in “Translational Andrology and Urology” Finasteride for hair loss may cause lasting sexual, genitourinary, mental, and anti-androgenic side effects in young men.
Dutasteride can stabilize hair loss in patients with frontal fibrosing alopecia, but its safety in women is unclear, so use it with caution.
2 citations,
April 2016 in “The Journal of Urology” Finasteride 1mg linked to diverse symptoms; other treatments improve erectile function in rats.
1 citations,
March 2016 in “Journal of The American Academy of Dermatology” More research needed to confirm finasteride as standard treatment for FFA.
August 2024 in “Research Square (Research Square)” Using 5-alpha reductase inhibitors may lower the risk of breast cancer in females.
June 2023 in “Research Square (Research Square)” A higher genetic risk score increases the chance of getting benign prostatic hyperplasia and affects treatment outcomes in Han Chinese men.
January 2023 in “The Egyptian Journal of Hospital Medicine” Dutasteride is effective for treating hair loss.
May 2016 in “The Journal of Sexual Medicine” Younger people (median age 35) experience more PFS-like symptoms with 1mg finasteride; more research needed.
18 citations,
June 2017 in “Journal of the neurological sciences” Using 5 alpha reductase inhibitors may increase dementia risk in the first two years.
15 citations,
January 2017 in “Advances in Experimental Medicine and Biology” 5α-Reductase inhibitors can negatively affect male sexual function and, in some cases, significantly reduce sperm count, but these effects may be reversible.
2 citations,
October 2021 in “Asian Journal of Andrology” Medications for hair loss and prostate issues can significantly increase the risk of sexual side effects and other negative symptoms.
April 2019 in “The Journal of urology/The journal of urology” Prescriptions for 5-alpha reductase inhibitors dropped significantly after the FDA's safety warning, especially for men with benign prostatic hyperplasia.
5 citations,
November 2020 in “medRxiv (Cold Spring Harbor Laboratory)” 5-Alpha-Reductase inhibitors shorten COVID-19 recovery time in men.
4 citations,
April 2020 in “medRxiv (Cold Spring Harbor Laboratory)” Men taking 5-alpha reductase inhibitors for prostate issues may be less likely to experience severe COVID-19, but it doesn't prevent ICU admission or death.
66 citations,
April 2017 in “International Journal of Andrology” Men taking 5α-reductase inhibitors for enlarged prostate have a higher chance of experiencing reduced sexual desire and erectile dysfunction.
19 citations,
October 2018 in “PLOS ONE” 5 alpha-reductase inhibitors can slightly improve symptoms of enlarged prostate but have a high risk of sexual side effects.
1 citations,
January 2020 in “Skin appendage disorders” Finasteride may help treat frontal fibrosing alopecia, but more research is needed.
October 2008 in “The Journal of Urology” Finasteride reduces prostate cancer risk but may increase high-grade tumors and has side effects; biopsy methods have similar outcomes; psychosocial factors affect sexual recovery post-surgery.
195 citations,
February 2007 in “The Journal of Clinical Endocrinology and Metabolism” Dutasteride and finasteride may reduce sperm count and volume but don't affect movement or shape; effects are reversible after stopping.
4 citations,
April 2018 in “British Journal of Dermatology” Finasteride for female hair loss has low side effects, more research needed.
2 citations,
March 2019 in “American journal of physiology. Renal physiology./American journal of physiology. Renal physiology” New treatments targeting fibrosis could improve urinary symptoms in BPH.
1 citations,
March 2021 in “The Journal of Sexual Medicine” The letter suggests testosterone replacement therapy might worsen COVID-19 outcomes.
April 2024 in “International journal of impotence research” Some men experience persistent sexual, neurological, and psychological symptoms after stopping finasteride, but evidence of permanent damage is inconclusive.
May 2017 in “Urology and andrology” Finasteride and dutasteride, used for prostate issues and hair loss, can cause side effects like sexual dysfunction and mental issues, which may continue even after stopping the medication, a condition called post-finasteride syndrome, for which there's currently no cure.
3 citations,
April 2013 in “International Journal of Clinical Practice” Combination therapy for 9+ months maintains symptom improvements after stopping alpha-blockers or finasteride.
2 citations,
July 2013 in “ISRN Urology (Print)” Finasteride may reduce bleeding after TURP, but more research needed.
November 2020 in “Journal of The American Academy of Dermatology” Men with male pattern baldness may be more at risk for severe COVID-19, and anti-androgen treatments could offer protection.
June 2018 in “The Journal of Sexual Medicine” Gray-scale ultrasound effectively detects erectile tissue fibrosis in young men with erectile dysfunction after using finasteride.
90 citations,
March 2017 in “JAMA Internal Medicine” Men over 66 taking medication for prostate enlargement have a higher risk of depression and self-harm, especially in the first 18 months of treatment.
22 citations,
August 2014 in “Clinical endocrinology” Taking finasteride for benign prostate hyperplasia may increase the risk of osteoporosis, especially at higher doses.